Eli Lilly price target raised to $892 from $850 at Truist

Truist analyst Robyn Karnauskas raised the firm’s price target on Eli Lilly to $892 from $850 and keeps a Buy rating on the shares. The company’s Q1 revenue was “solid”, driven by Mounjaro/Zepbound, and its strong performance and underlying demand seem healthy, the analyst tells investors in a research note. The management’s raised guidance is also reflected in increased Mounjaro//Zepbound revenues given the ramp up in supply and capacity, the firm added.